– UK, Guildford – Futura Medical plc (LON: FUM) today announced the appointment of Jeff Needham to its Board as a non-executive director with immediate effect.
“We are delighted to welcome Jeff, a seasoned and highly respected industry leader, to the Board of Directors. His unparalleled management, strategic and corporate expertise, especially in Consumer Health, OTC and the USA underscores our ambition and focus on building a global brand to deliver MED3000, our breakthrough treatment for erectile dysfunction to sufferers as a therapy option without the need for a doctor’s prescription.” said CEO, James Barder.
About Jeff Needham
Jeff Needham brings a wealth of knowledge and experience to the Board having been at Perrigo Company plc, the US-based manufacturer and marketer of consumer healthcare products, for 36 years, and a board director of the Consumer Healthcare Products Association for 12 years. Whilst at Perrigo, Jeff was responsible for the consumer self-care businesses in the Americas, that included Perrigo’s US OTC Drug business, Nutritionals, Oral Care, and its businesses in Mexico and Canada. Jeff’s focus was on the development and long-term strategic direction of the business, including marketing, sales, new product pipeline development, business development, and scientific affairs.
About Futura Medical plc
Futura Medical plc is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys technology. Each DermaSys formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimized for clinical efficacy, safety, administration, and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialization strategies are designed to maximize product differentiation and value creation whilst minimizing risk.
MED3000 is Futura’s topical gel formulation that is a breakthrough treatment for erectile dysfunction through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as “FM57”. This was a 1,000 patient, dose-ranging, multi-center, randomized, double-blind, placebo-controlled, home use, parallel-group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2, and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED. MED3000 also begins to work immediately in some patients, with 60% of patients seeing the onset of their erection within 10 minutes of application. MED3000 is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction.
For more information: https://www.futuramedical.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.